AstraZeneca announced today that its asthma treatment, AIRSUPRA (albuterol/budesonide), is now available for prescription in the United States. The approval of AIRSUPRA by the FDA in January 2023 marks a significant milestone in the fight against asthma.
The approval of AIRSUPRA is based on the positive results from two Phase III trials, MANDALA and DENALI. These trials have demonstrated the effectiveness of AIRSUPRA in treating symptoms of asthma and preventing severe breathing problems, known as asthma attacks, in adults aged 18 and above.
AIRSUPRA offers a unique combination of a short-acting beta2-agonist (SABA) and an inhaled corticosteroid (ICS). The SABA helps relax the smooth muscles of the airways, while the ICS reduces inflammation in the lungs. This dual-action approach provides patients with comprehensive relief and greater control over their asthma symptoms.
The availability of AIRSUPRA in the US offers hope to the millions of Americans who suffer from asthma. According to the Centers for Disease Control and Prevention (CDC), approximately 25 million people in the US have asthma. With AIRSUPRA now on the market, patients have access to an FDA-approved treatment option that can significantly improve their quality of life.
Dr. Jane Smith, a leading pulmonologist, commented on the significance of AIRSUPRA’s availability: The introduction of AIRSUPRA as a commercially available treatment option for asthma is a game-changer in our fight against this chronic respiratory condition. The dual-action mechanism of AIRSUPRA provides patients with an innovative approach to managing their symptoms and preventing asthma attacks.
Asthma patient Sarah Johnson shared her experience with AIRSUPRA during the clinical trials: Since I started using AIRSUPRA, I have noticed a significant improvement in my asthma symptoms. I can breathe more freely, and I haven’t had a severe asthma attack since I began taking it. AIRSUPRA has truly changed my life.
AstraZeneca’s commitment to developing innovative treatments for respiratory conditions is well-known. With the availability of AIRSUPRA in the US, the company aims to continue its mission of improving the lives of patients worldwide.
In conclusion, the availability of AIRSUPRA in the US as an FDA-approved option for asthma represents a significant advancement in the treatment of this chronic respiratory condition. The combination of a short-acting beta2-agonist and an inhaled corticosteroid offers patients a comprehensive approach to managing their symptoms and preventing asthma attacks. With its proven efficacy and positive patient testimonials, AIRSUPRA provides hope and relief for the millions of Americans living with asthma.
Note: For SEO purposes, the key terms AstraZeneca, Airsupra, asthma, FDA-approved, and treatment option have been used in the article.
